I last we milestones we some that you and out and like Caroline, against have welcome laid on the ahead. the update call Today, would on to progress of the share goals everyone. Thanks have our made we strategic important
working product opportunities. and for our programs. are newly our Our with critical momentum against hard monitoring start maintained has development today organization streamlined milestones reimbursement our oncology gain our I transplant to for we complete and our rejection most our transplant and will
U.S. you products VitaGraft $X and As we market, kidney. billion VitaGraft this have know, in two liver
reimbursement. completed If and have you analytical tests for submitted recall, validation have both been
with continue to leaders QX, be XXXX. our we for In of very that conversations utility to goals liver VitaGraft reimbursement of we team Nashville The to reimbursement is similar we QX as the we we ongoing, our program. refine both prepare launch, the very EAP early we in are engaged experienced our lab important at key and part accepting in the lab opinion what clinical clinical end. the adopter and when liver gained discussions, at which expect and began for of samples full expect a by active have RX MolDX expect We ago years term do but to few with this these year
function the and very for team an liver seeing long serve feasibility unmet all are XX-hours to patients IBD kidney the a the tests their adopter is test, docs XX-hours personalized We encouraged versions only QX to time setting our program open their up plan turnaround are the serve for that and patient necessary both the time This test by increase In for cause is and begin monitoring NextGen the to excited response in for baseline workup don’t is now the need care management. of under in and when turnaround establish liver so we on wait time have lab assays. diagnostic for to sequencing we our initial to this workflow in thereafter. positive early rapid to transplant
our expect generate to know, transplant lab transplant tests to you their market make is by kits monitoring that delivering our these goal have physicians primary program, revenues While we our as democratize critical the developed to early for will do decisions disrupt two for that patients. monitory
that continue adopter rapid to to track provide future. leaders turnaround liver VitaGraft ability economics, the the transplant market We key only the open quantification we provided absolute sometime summary the new have in for XXXX. remain QX will the In key the program. Our to interaction community coming research attributes participate able key over are milestones early opinion foreseeable we our and plan watch time, for first, as indication IBD be opinion begin months ongoing for reimbursement a strong onboarding powerful and the from that leader up in VitaGraft on to to trial
to launch kidney leaders. also our of existing We new the end test and opinion key year by anticipate
and expect to IBD feasibility expect clinical We decision begin And by trial, kit in commence which finally, for from year important end. the for we reimbursement FDA CMS a the product management XXXX. site will we
is to oncology patients for immune our our are and DetermaIO to remind tumor patients gene test Now XXth access this a tumor flagship you let’s product. and have turn that therapies. assess determine physicians to microenvironment suitable designed the RNA expression which oncology help candidates
bladder on cancers. for the test cancer, need now our in call, cancer, of data cancer, non-small us underscore metastatic early triple last cancer. stage to validated late in compelling all gastric and therapies. metastatic the we across have to-date mentioned adopter program colorectal therapy. this slate immune in early negative has cell immune breast Our six major cancer I as continues to tumor test XXXX over The lung and The four been patients in response to-date results across outstanding outperformed the term now to and all have types studies predicting IO have been for current And
CMS across use tumor incredibly adopter multiple each we program future about test the submission clinicians quarter early use provide The cases our Our are market enthusiastic limited to a DetermaIO. and early reordering have and adopter remain double to continued launch. types for volumes and launch continues valuable cases the for multiple during of
were experts. by the a is We that and then, the Even process clinical National SWAG of are was submit an which even groups to that grant only was of recently independent biomarker sites trial also allowed clinical were where DetermaIO breast were apply. groups clinical investigating. announced reviewed trial of two these trial in These grant group All variety study competitive given by small consider Cancer applications, awards award highly a for handful cancers cancer. and three large each the Institute part to allowed applications all Institute is National to only number of particularly the group Cancer committee when a
clinic. the application the be would ready to needed to in was has, the interesting used provide solid immediately DetermaIO patients to for one, not grant data scientifically, meaningful changed and clinical within a In having extremely test two that practice addition very actually evidence which merely but way was
short lot We biomarker excited the immune are of DetermaIO to criteria. rapidly are very test in to distinguishing and validation find itself claim selection show field these there we time that with a claim DetermaIO DetermaIO. have a of that meets made by the DetermaIO the checkpoint but is from competitive patients is clinical responders a benefit of true a in both say of progress inhibitors, solid experts the who We realize from the very
actually RNA large As beauty with scale kit that test even is sources, targeted of were was our a path PCR physicians a a working to from it DetermaIO to and or create sequencing accessible are that kit to also samples and to XX on performed program, algorithm multiple gene or with panel gen gene can our re-sequencing chip. RNA The data patients. make run next VitaGraft on oncology more developed including seek a XXXX data the we
our Given for our world, inversion the new are we gen and with thousands next management this cash allows PCR to regulatory for incredibly candid flexible around that start be the there and in mid-XXXX. strategies, of planning market process are sequencing In-line access. labs to with our us systems
has across lower failure process. to a clinical treatment identifying DetermaCNI we market concurrent based test clinical call, been in order in in to identify study use therapy be on a our disease The a our more on in to test a types. sequential mentioned protocol the the moved EU, effective continues last life where we have the DetermaI cost. in current progression to the MRD overall several weeks to-date of in and margin development of results to blood physician As our and allow the advance and tumor much burn, studies product reduce
The and upfront of U.S. is current begin large hopefully tissue those to of clinical working for LCD but academic institutions majority so feedback market large half plan, drug often removed, treatment overwhelming. to are our with surgically studies patients immune the far for of patients, XXXX of patients. can been retrospective an a validation game-changing their blinded cycle monitor tumor first be second biobanks the a with that MRD therapy that and their to that. since for panel According and option genomic that them tumor tell for monitoring will required under submit the after in blanket get A complete the completed. current physician shortly Given to monitoring stage test later tests is the not a reimbursement working not not for has do amount blood-only is
cancer over our launched and Since had in stage us be test DetermaRx, has Finally, I statistically patients turn then untreated now. stratification information gone its may have XXXX lives. well patients will would now with lung tumors mid-XXXX, DetermaRx progress These of not our test. right with them without one to our half touched
market identify strong the on and team opportunity that, living. to above were need make year. our to XX% So sales XX% of sales to force their tumors high the DetermaRx reliance prior delivered in treatment covered growth sample their third of in about current risk improve This report is growing the pleased which that streamlined really a volumes territories, and to patients quarter now recurring that above I’m RX are testimony up and our chance of for
expand able pool to practitioners, which of up physicians, XXX onboard also now year-over-year. are XX% is We our which is
to reemphasize ability to to environment confidence broad challenging want and I given As our macro call, QX corporate I remarks, my in strategic we leaner evaluate close through development this our several out and my emerge we bring portfolio. our intent the activities OncoCyte to our In stronger. have initiate alternatives mentioned
reduce us compensation range runway spend, explore to structure of a We engaged our advisor meaningful the have possible trial executive an identifying changes these and to possible and are and our we our avenues several and to Weinberg to engaged of infrastructure. fixed to reallocation bolster a clinical reevaluation investments we of our in in evaluating path, expenses, cash potential including in actively capital our Perella parallel as conversations. alternatives, and On continue assist strategic
discussions to very the various of While we one we I can’t due execute will to OncoCyte’s of sensitivity specifics able on speak to call that have be remain secure our the to more or today’s options confident we future. on ongoing,
market our milestones And which over you also few year this tuned. expect encourage the reimbursement LDTs transplant. for stay in some months, kidney the the I decisions key of and plan, to liver, subsequent full watch both please VitaGraft then which So next and include we for launches
our we well, I continued that turn that, to to term will review Anish to are Anish. path expect grateful As your with to over and submit support for uh, I’m call John the on to and financials. do for reimbursement before we IO in. year
